Advances in patent applications related to cancer vaccine using CpG-ODN and OX40 association [0.03%]
与癌症疫苗相关的专利申请进展：CpG-ODN和OX40相关性
Cristina M Quintella,Heitor M Quintella,Mayla Rohweder et al.
Cristina M Quintella et al.
Introduction: This review aims to assess the available technologies, advances, and trends from technological readiness level 4 to level 8 for cancer immunologic therapeutics using the association of OX40 and CPG-ODN, usually known as cancer...
Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present) [0.03%]
组蛋白去乙酰酶(HDAC)抑制剂在癌症治疗中的应用(2017-至今)——专利回顾
Chunlong Zhao,Hang Dong,Qifu Xu et al.
Chunlong Zhao et al.
Introduction: Histone deacetylase (HDAC) inhibitors play a crucial role in restoring the balance of acetylation and deacetylation of lysine residues of histones and non-histone proteins, which are applied to treat several diseases including...
Rishi Paliwal,Shivani Rai Paliwal,Rameshroo Kenwat et al.
Rishi Paliwal et al.
Introduction: Solid lipid nanoparticles (SLNs) are solid core lipid nanocarriers, which can hold both hydrophilic and hydrophobic drugs. They can be made up of biocompatible ingredients and therefore are one of the preferred choices for dru...
Gyllyandeson De Araújo Delmondes,Izabel Cristina Santiago Lemos,Diógenes De Queiroz Dias et al.
Gyllyandeson De Araújo Delmondes et al.
Introduction: Farnesol (C15H26O) is a sesquiterpene alcohol found in essential oils. This substance is reported to have different pharmacological activities such as antimicrobial, antitumor and antioxidant effects, as well as actions in dif...
Treatment of cancer with an anti-KIR antibody: a patent evaluation of US9879082 and US2018208652 [0.03%]
一种治疗癌症的抗KIR抗体的专利评估美国发明专利US9879082和申请号US2018208652
Martin Perez-Santos,Tayde Guerrero-González,Eduardo Gómez-Conde et al.
Martin Perez-Santos et al.
Introduction: KIR is an inhibitory receptor expressed by natural killer cells that suppress the immune response against tumor cells. There is a great need to discover and develop new therapies focused on inhibiting the action of KIR and con...
A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor [0.03%]
卡博特格拉韦的专利文献回顾——HIV整合酶链转移抑制剂类药物的研究进展
Lidija Kovač,Zdenko Časar
Lidija Kovač
Introduction: Studies presented in the patent applications demonstrate that a new integrase strand transfer inhibitor cabotegravir might be used as long-acting antiretroviral formulation or delivery system that reduces dosing frequency and ...
Recent progress in the development of small molecule Nrf2 activators: a patent review (2017-present) [0.03%]
近五年小分子Nrf2激活剂的研发进展（2017-今）——基于专利的文献回顾
Haishan Zhou,Yan Wang,Qidong You et al.
Haishan Zhou et al.
Introduction: The transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) is the first line of defense against a plethora of environmental or endogenous deviations in redox metabolism, proteostasis, inflammation, etc. Theref...
Covalent inhibitors of the GTPase KRASG12C: a review of the patent literature [0.03%]
共价抑制KRASG12C鸟苷三磷酸酶：专利文献综述
Jason G Kettle,Doyle J Cassar
Jason G Kettle
Introduction: KRAS is one of the most important oncology drug targets, playing a pivotal role in the initiation and progression of many human tumors. It has long been held undruggable due to many previously failed attempts to both directly ...
Dermatophagoides spp. hypoallergens design: what has been achieved so far? [0.03%]
粉尘螨低变应原设计：迄今为止取得了哪些成果？
Eduardo Santos da Silva,Carina Silva Pinheiro,Luis Gustavo Carvalho Pacheco et al.
Eduardo Santos da Silva et al.
Introduction: Allergic illnesses are one of the most prevalent immunological disorders worldwide and house dust mites are important triggers of these diseases. Allergen-specific immunotherapy (AIT) is an alternative treatment to pharmacothe...
Phosphodiesterase 10 (PDE10) inhibitors: an updated patent review (2014-present) [0.03%]
磷二酯酶10(PDE10)抑制剂专利回顾(2014-至今)
Agnieszka Zagórska
Agnieszka Zagórska
Introduction: Phosphodiesterase 10 (PDE10) is one of at least 11 different PDE families, which are the enzymes that degrade adenosine 3',5'-cyclic monophosphate (cAMP) and/or guanosine 3',5'-cyclic monophosphate (cGMP) by hydrolyzing the ph...